Your browser doesn't support javascript.
loading
COX-2 mediates tumor-stromal prolactin signaling to initiate tumorigenesis.
Zheng, Yu; Comaills, Valentine; Burr, Risa; Boulay, Gaylor; Miyamoto, David T; Wittner, Ben S; Emmons, Erin; Sil, Srinjoy; Koulopoulos, Michael W; Broderick, Katherine T; Tai, Eric; Rengarajan, Shruthi; Kulkarni, Anupriya S; Shioda, Toshi; Wu, Chin-Lee; Ramaswamy, Sridhar; Ting, David T; Toner, Mehmet; Rivera, Miguel N; Maheswaran, Shyamala; Haber, Daniel A.
Afiliação
  • Zheng Y; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Comaills V; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Burr R; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Boulay G; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Miyamoto DT; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Wittner BS; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Emmons E; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Sil S; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Koulopoulos MW; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Broderick KT; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Tai E; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Rengarajan S; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Kulkarni AS; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Shioda T; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Wu CL; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Ramaswamy S; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Ting DT; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Toner M; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Rivera MN; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
  • Maheswaran S; Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Haber DA; Massachusetts General Hospital Cancer Center,Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
Proc Natl Acad Sci U S A ; 116(12): 5223-5232, 2019 03 19.
Article em En | MEDLINE | ID: mdl-30819896

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactina / Neoplasias da Próstata / Transdução de Sinais / Células Estromais / Carcinogênese Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prolactina / Neoplasias da Próstata / Transdução de Sinais / Células Estromais / Carcinogênese Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2019 Tipo de documento: Article